ARC1779 for TTP
31 views
Skip to first unread message
skharoon
Sep 9, 2008, 1:49:48 AM9/9/08
to Congenital TTP
Hi,
I have found one article on internet drug for TTP.
Has any one knows about this....
Pls reply.....
-------------------------------------------------------------------------------------------------------------
ARC1779 for TTP
ARC1779 is currently in Phase 2 clinical development with a clinical
trial designed to assess the safety, pharmacokinetics and
pharmacodynamic effects of ARC1779 in approximately 28 patients with
vWF-mediated platelet function disorders, including acute TTP.
Archemix expects this trial to conclude in 3Q 2008.
http://www.archemix.com/website/index.php
http://www.archemix.com/website/products_1779_ttp.php
Archemix’ ARC1779 Granted Orphan Designation in EU for the Treatment
of
TTP, a Life-Threatening Blood Disorder
http://www.archemix.com/website/_popup_press_release.php?release=49
Archemix’ ARC1779 Granted Orphan Designation for the Treatment of TTP,
a
Life-Threatening Blood Disorder
http://www.archemix.com/website/_popup_press_release.php?release=48
Archemix Announces Initiation of Phase 2 Trial for Aptamer Product
Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood
Disorder
http://www.archemix.com/website/_popup_press_release.php?release=47
Product Pipeline
http://www.archemix.com/website/products.php
-------------------------------------------------------------------------------------------------------------
I have found one article on internet drug for TTP.
Has any one knows about this....
Pls reply.....
-------------------------------------------------------------------------------------------------------------
ARC1779 for TTP
ARC1779 is currently in Phase 2 clinical development with a clinical
trial designed to assess the safety, pharmacokinetics and
pharmacodynamic effects of ARC1779 in approximately 28 patients with
vWF-mediated platelet function disorders, including acute TTP.
Archemix expects this trial to conclude in 3Q 2008.
http://www.archemix.com/website/index.php
http://www.archemix.com/website/products_1779_ttp.php
Archemix’ ARC1779 Granted Orphan Designation in EU for the Treatment
of
TTP, a Life-Threatening Blood Disorder
http://www.archemix.com/website/_popup_press_release.php?release=49
Archemix’ ARC1779 Granted Orphan Designation for the Treatment of TTP,
a
Life-Threatening Blood Disorder
http://www.archemix.com/website/_popup_press_release.php?release=48
Archemix Announces Initiation of Phase 2 Trial for Aptamer Product
Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood
Disorder
http://www.archemix.com/website/_popup_press_release.php?release=47
Product Pipeline
http://www.archemix.com/website/products.php
-------------------------------------------------------------------------------------------------------------
in...@congenitalttp.com
Sep 9, 2008, 8:53:22 AM9/9/08
to Congenital TTP
Thank you for the information. I am going to check with our
Hemetologist.
On Sep 9, 12:49 am, skharoon <skhar...@gmail.com> wrote:
> Hi,
>
> I have found one article on internet drug for TTP.
>
> Has any one knows about this....
>
> Pls reply.....
>
> -------------------------------------------------------------------------------------------------------------
Hemetologist.
On Sep 9, 12:49 am, skharoon <skhar...@gmail.com> wrote:
> Hi,
>
> I have found one article on internet drug for TTP.
>
> Has any one knows about this....
>
> Pls reply.....
>
>
> ARC1779 for TTP
>
> ARC1779 is currently in Phase 2 clinical development with a clinical
> trial designed to assess the safety, pharmacokinetics and
> pharmacodynamic effects of ARC1779 in approximately 28 patients with
> vWF-mediated platelet function disorders, including acute TTP.
> Archemix expects this trial to conclude in 3Q 2008.
>
> http://www.archemix.com/website/index.phphttp://www.archemix.com/website/products_1779_ttp.php
> ARC1779 for TTP
>
> ARC1779 is currently in Phase 2 clinical development with a clinical
> trial designed to assess the safety, pharmacokinetics and
> pharmacodynamic effects of ARC1779 in approximately 28 patients with
> vWF-mediated platelet function disorders, including acute TTP.
> Archemix expects this trial to conclude in 3Q 2008.
>
>
> Archemix’ ARC1779 Granted Orphan Designation in EU for the Treatment
> of
> TTP, a Life-Threatening Blood Disorderhttp://www.archemix.com/website/_popup_press_release.php?release=49
> Archemix’ ARC1779 Granted Orphan Designation in EU for the Treatment
> of
>
> Archemix’ ARC1779 Granted Orphan Designation for the Treatment of TTP,
> a
> Life-Threatening Blood Disorderhttp://www.archemix.com/website/_popup_press_release.php?release=48
> Archemix’ ARC1779 Granted Orphan Designation for the Treatment of TTP,
> a
Juan Lo
Sep 10, 2008, 10:48:48 AM9/10/08
to congeni...@googlegroups.com
This is the first I hear of this. Looks promising.
Reply all
Reply to author
Forward
0 new messages